Quest PharmaTech Inc.'s Subsidiary, OncoQuest, Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer
EDMONTON, AB – Quest PharmaTech Inc., announces that its subsidiary, OncoQuest Inc., a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, has completed the enrollment of the first patient in a Phase 1/2 clinical study to evaluate the use of oregovomab in combination with Nivolumab, an anti-PD1 human monoclonal antibody which works as a checkpoint inhibitor in ovarian cancer patients in the recurrent setting.